This represents a step forward for the plant-based protein purification industry, with the first compact bed chromatography system for the purification of vegetable proteins.
With this new Viral Vector bioproduction facility, Novasep confirms its leadership position and effectively addresses the growing gene therapy market demand
Novasep’s robust quality assurance system, fully compliant with the highest world standards, showcased during successful FDA inspection of the Chasse-sur-Rhône (France) facility.
BioSC Pilot® is a new tool for continuous and intensified downstream processes in the biopharmaceutical industry.
This facility, located in Seneffe (Belgium), will strengthen Novasep’s drug product services for mAbs, viral vectors and other low volume biopharmaceuticals
Sales are up 4% at 282 M€
EBITDA is up 4.3% at 29 M€
The starch sweeteners plant will serve the growing Middle Eastern food and beverage market.
The manufacturing will take place at Novasep’s Chasse sur Rhône site.
The facility will address increasing demand for small-volume mAb CDMO services
• Egyptian producer Al Nouran’s future sugar production facility integrates Novasep-engineered purification units
• The new plant to address local supply shortage